Status:
RECRUITING
Autonomic Modulation in Takotsubo Syndrome
Lead Sponsor:
NYU Langone Health
Conditions:
Takotsubo Syndrome
Eligibility:
All Genders
21+ years
Phase:
NA
Brief Summary
This is a minimal risk case-controlled single arm intervention study, including 10 patients with a prior history of takotsubo and 10-age and sex matched healthy controls. Subjects will undergo in labo...
Eligibility Criteria
Inclusion
- Confirmed history of takotsubo syndrome
- Healthy person with no significant past history of cardiovascular or neurological disease such as heart failure or heart attack; people with cardiovascular risk factors such as hypertension will be permitted to participate
Exclusion
- Pacemaker or defibrillator implanted
- Evidence of autonomic neuropathy, alcohol or drug abuse or exposure to neurotoxins (chemotherapy).
- Diabetes
Key Trial Info
Start Date :
October 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2027
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT03324529
Start Date
October 1 2021
End Date
June 1 2027
Last Update
March 26 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
New York University School of Medicine
New York, New York, United States, 10016